# REGENXBIO Inc. (RGNX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.94, market value $590 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). REGENXBIO Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.4×**. Each dollar of revenue is priced at 3.4×.
- **Price / book: 6.7×**. The shares trade at 6.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -42.3%** (5-yr avg -21.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -94.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -113.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -188.7%**. Return on equity is negative because earnings are negative.
- **Return on assets: -43.4%**. Each dollar of assets produces -43.4% of profit.

## Growth
- **Revenue growth (1 yr): 104.5%** (3-yr 14.8%/yr, 5-yr 2.0%/yr). Revenue grew 104.5% over the last year, against 2.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 18.1%**. Earnings per share rose 18.1%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 2.38** (quick 2.38). Current assets cover the next year's liabilities 2.38 times.
- **Altman Z-score: 0.96**. A Z-score of 0.96 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. REGENXBIO Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (11 analysts). 11 analysts cover REGENXBIO Inc.; the consensus is buy, with an average price target of $23.73 (+165% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -5.1%** (YTD -37.9%, 3-mo 47.0%). The shares are down 5.1% over twelve months including dividends.
- **From 52-week high: -44.8%** (63.9% above the low). Trading 45% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 2.08** (volatility 93%). Beta of 2.08 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RGNX · Page: https://foliofundamentals.com/stocks/rgnx

Not investment advice.